Table 4.
Study population: clinical, treatment and outcome features.
| N° | Clinical Signs | Pleural Effusion | Tumour Location | Total Number of VRL Administrations | VCOG Toxicity | TTP (Days) | ST (Days) |
|---|---|---|---|---|---|---|---|
| 1 | None | NO | Pulmonary + Hepatic Mts | 8 | A grade II V grade I |
88 | 160 |
| 2 | Dyspnea | YES | Diffuse Pulmonary | 8 * | N grade IV V grade I |
84 | 635 |
| 3 | Weight Loss | NO | Diffuse Pulmonary | 10 | NO | 112 | 120 |
| 4 | Weight Loss | NO | Hepatic Mts | 8 | NO | 90 | 90 |
| 5 | Dyspnea | YES | Diffuse Pulmonary + Hepatic Mts | 1 | NV | 7 | 7 |
| 6 | Cough | NO | Diffuse Pulmonary | 8 * | N grade II | 84 | 100 |
| 7 | Weight Loss | NO | Diffuse Pulmonary | 8 * | NO | 90 | 90 |
| 8 | None | NO | Diffuse Pulmonary | 9 | N grade II | 98 | 100 |
| 9 | Dyspnea | YES | Diffuse Pulmonary | 8 | N grade I | 84 | 90 |
| 10 | None | NO | Diffuse Pulmonary | 10 | N grade I | 112 | 120 |
Legend: A: anorexia; N: neutropenia; V: vomiting; TTP: time to progression; ST: survival time. *: concurrent piroxicam treatment.